myelodysplastic syndromes

Summary

Summary: Conditions in which the bone marrow shows qualitative and quantitative changes suggestive of a preleukemic process, but having a chronic course that does not necessarily terminate as acute leukemia.

Top Publications

  1. ncbi The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    James W Vardiman
    Department of Pathology, University of Chicago, IL, USA
    Blood 114:937-51. 2009
  2. ncbi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
  3. ncbi Frequent pathway mutations of splicing machinery in myelodysplasia
    Kenichi Yoshida
    Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Nature 478:64-9. 2011
  4. ncbi Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Pierre Fenaux
    Hopital Avicenne, Universite Paris XIII, Bobigny, France
    Lancet Oncol 10:223-32. 2009
  5. ncbi Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
    Gorica Nikoloski
    Department of Laboratory Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    Nat Genet 42:665-7. 2010
  6. ncbi Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype
    Daniel T Starczynowski
    British Columbia Cancer Agency Research Centre, Vancouver, British Columbia, Canada
    Nat Med 16:49-58. 2010
  7. ncbi Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1060-6. 2008
  8. ncbi Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts
    E Papaemmanuil
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    N Engl J Med 365:1384-95. 2011
  9. ncbi Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006
  10. ncbi Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
    Br J Haematol 145:788-800. 2009

Research Grants

  1. NF1 GENE IN MYELOID LEUKEMIA AND CYTOKINE SIGNALING
    DAVID LARGAESPADA; Fiscal Year: 2002
  2. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2010
  3. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2011
  4. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Pearlie K Epling Burnette; Fiscal Year: 2009
  5. A mouse model of myelodysplastic syndrome progression and leukemic stem cells
    Yupo Ma; Fiscal Year: 2009
  6. MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS
    Edward Newman; Fiscal Year: 2001
  7. New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)
    Elihu Estey; Fiscal Year: 2007
  8. Cyclin E Regulation in Normal and Neoplastic Hematopoiesis
    ALEXANDER C MINELLA; Fiscal Year: 2010
  9. FMS TRANSFORMATION/CSF-1 RECEPTOR SIGNAL TRANSDUCTION
    Martine Roussel; Fiscal Year: 1993
  10. The Role of the APC Tumor Suppressor Gene in Hematopoiesis and Leukemogenesis
    Zhijian Qian; Fiscal Year: 2010

Detail Information

Publications284 found, 100 shown here

  1. ncbi The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    James W Vardiman
    Department of Pathology, University of Chicago, IL, USA
    Blood 114:937-51. 2009
    ....
  2. ncbi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
    The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. The mechanisms underlying these disorders are not well defined.
  3. ncbi Frequent pathway mutations of splicing machinery in myelodysplasia
    Kenichi Yoshida
    Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Nature 478:64-9. 2011
    b>Myelodysplastic syndromes and related disorders (myelodysplasia) are a heterogeneous group of myeloid neoplasms showing deregulated blood cell production with evidence of myeloid dysplasia and a predisposition to acute myeloid leukaemia, ..
  4. ncbi Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Pierre Fenaux
    Hopital Avicenne, Universite Paris XIII, Bobigny, France
    Lancet Oncol 10:223-32. 2009
    Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage...
  5. ncbi Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
    Gorica Nikoloski
    Department of Laboratory Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    Nat Genet 42:665-7. 2010
    In myelodysplastic syndromes (MDS), deletions of chromosome 7 or 7q are common and correlate with a poor prognosis. The relevant genes on chromosome 7 are unknown. We report here that EZH2, located at 7q36...
  6. ncbi Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype
    Daniel T Starczynowski
    British Columbia Cancer Agency Research Centre, Vancouver, British Columbia, Canada
    Nat Med 16:49-58. 2010
    ..Thus, inappropriate activation of innate immune signals in HSPCs phenocopies several clinical features of 5q- syndrome...
  7. ncbi Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1060-6. 2008
    ..Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible...
  8. ncbi Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts
    E Papaemmanuil
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    N Engl J Med 365:1384-95. 2011
    b>Myelodysplastic syndromes are a diverse and common group of chronic hematologic cancers. The identification of new genetic lesions could facilitate new diagnostic and therapeutic strategies.
  9. ncbi Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006
    Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy...
  10. ncbi Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
    Br J Haematol 145:788-800. 2009
    The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal haematological diseases characterized by ineffective haematopoiesis and predisposition to acute myeloid leukaemia (AML). The pathophysiology of MDSs remains unclear...
  11. ncbi Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
    W T Bellamy
    Department of Pathology, and the Bone Marrow Transplant Program, The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Blood 97:1427-34. 2001
    ....
  12. ncbi Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
    Andres O Soriano
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2302-8. 2007
    ..VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170...
  13. ncbi Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
    M J Walter
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, MO 63110, USA
    Leukemia 25:1153-8. 2011
    Alterations in DNA methylation have been implicated in the pathogenesis of myelodysplastic syndromes (MDS), although the underlying mechanism remains largely unknown...
  14. ncbi A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  15. ncbi Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)
    I Kotsianidis
    Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece
    Leukemia 23:510-8. 2009
    ..In myelodysplastic syndromes (MDS), immune deregulation and autoimmunity in the early stages might lead to ineffective hematopoiesis ..
  16. ncbi Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
    ..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
  17. ncbi Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
    Ying Jiang
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, OH 44195, USA
    Blood 113:1315-25. 2009
    b>Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an intermediate disease stage before progression to acute myeloid leukemia (AML)...
  18. ncbi MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
    Maria E Figueroa
    Department of Medicine Hematology Oncology Division, Weill Cornell Medical College, New York, NY 10065, USA
    Blood 114:3448-58. 2009
    ..Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors...
  19. ncbi International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report
    Janet D Rowley
    Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Genes Chromosomes Cancer 33:331-45. 2002
  20. ncbi CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
    Shahram Y Kordasti
    Department of Hematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, UK
    Blood 110:847-50. 2007
    ..032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease...
  21. ncbi Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements
    Idoya Lahortiga
    Department of Genetics, University of Navarra, Pamplona, Spain
    Genes Chromosomes Cancer 40:179-89. 2004
    ..Our data suggest that a unique mechanism is not likely to be involved in 3q21q26 rearrangements...
  22. ncbi IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
    Haematologica 95:1668-74. 2010
    b>Myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders with a high propensity to transform into acute myeloid leukemia...
  23. ncbi Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia
    J Pedersen-Bjergaard
    The Chromosome Laboratory, Section of Hematology Oncology, Department of Clinical Genetics, Juliane Marie Center, Copenhagen, Denmark
    Leukemia 20:1943-9. 2006
    ....
  24. ncbi DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
    Elizabeth A Griffiths
    Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Semin Hematol 45:23-30. 2008
    ..Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease...
  25. ncbi Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis
    Timothy A Graubert
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS ONE 4:e4583. 2009
    ..2 are among the most common recurring cytogenetic abnormalities detectable in myelodysplastic syndromes (MDS). Prior genomic studies have suggested that haploinsufficiency of multiple 5q31...
  26. ncbi Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Dawn Hershman
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 99:196-205. 2007
    ..Although these growth factors support chemotherapy, their long-term safety has not been evaluated. We studied the association between G-CSF use and incidence of leukemia in a population-based sample of breast cancer patients...
  27. ncbi Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia
    Jens Pedersen-Bjergaard
    Cytogenetic Laboratory, Section 4052, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark
    Blood 99:1909-12. 2002
    ..Recent research suggests that these 2 general types of t-AML can now be subdivided into at least 8 genetic pathways with a different etiology and different biologic characteristics...
  28. ncbi A FISH comparison of variant derivatives of the recurrent dic(17;20) of myelodysplastic syndromes and acute myeloid leukemia: Obligatory retention of genes on 17p and 20q may explain the formation of dicentric chromosomes
    Ruth N MacKinnon
    Victorian Cancer Cytogenetics Service, St Vincent s Hospital Melbourne, Australia
    Genes Chromosomes Cancer 46:27-36. 2007
    The dic(17;20) is a recurrent unbalanced translocation occurring rarely in myelodysplastic syndromes and acute myeloid leukemia...
  29. ncbi Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
    Amanda F Cashen
    Washington University School of Medicine, St Louis, MO, USA
    J Clin Oncol 28:556-61. 2010
    ..We investigated the efficacy and toxicity of the hypomethylating agent decitabine as initial therapy in older patients with AML...
  30. ncbi Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
    Timothy A Graubert
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri, USA
    Nat Genet 44:53-7. 2012
    b>Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML)...
  31. ncbi Molecular bases of myelodysplastic syndromes: lessons from animal models
    Yukiko Komeno
    Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Cell Physiol 219:529-34. 2009
    ..In this review, we summarize the animal models of MDS and discuss the molecular bases of MDS as well as those of leukemia and myeloproliferative disorders (MPD). J. Cell. Physiol. 219: 529-534, 2009. (c) 2009 Wiley-Liss, Inc...
  32. ncbi Cytogenetic features in myelodysplastic syndromes
    Detlef Haase
    Department of Hematology and Oncology, Georg August University, Robert Koch Str 40, 37075, Gottingen, Germany
    Ann Hematol 87:515-26. 2008
    b>Myelodysplastic syndromes (MDS) comprise a group of bone marrow diseases characterized by profound heterogeneity in morphologic presentation, clinical course, and cytogenetic features...
  33. ncbi Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
    Katharina Götze
    III Medizinische Klinik, Technische Universitat Munchen, Ismaningerstrasse 15, Munich, Germany
    Ann Hematol 89:841-50. 2010
    b>Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a substantial risk of progression to acute myeloid leukemia (AML)...
  34. ncbi Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes
    Dominik Beck
    Bioengineering and Bioinformatics Program, Department of Pathology, The Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, TX, 77030, USA
    BMC Med Genomics 4:19. 2011
    b>Myelodysplastic Syndromes (MDSS) are pre-leukemic disorders with increasing incident rates worldwide, but very limited treatment options...
  35. ncbi Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Rese
    Michael Lubbert
    Albert Ludwigs University, Freiburg, Germany
    J Clin Oncol 29:1987-96. 2011
    ..To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy...
  36. ncbi Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
    R Itzykson
    Service d Hématologie Clinique Hôpital Avicenne, Assistance Publique Hopitaux de Paris AP HP, Universite Paris 13, Bobigny, France
    Leukemia 25:1147-52. 2011
    ..Response duration and overall survival were, however, comparable in the MUT and WT groups. In higher risk MDS and AML with low blast count, TET2 status may be a genetic predictor of response to AZA, independently of karyotype...
  37. ncbi TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
    Martin Jadersten
    Center for Experimental Hematology M54, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    J Clin Oncol 29:1971-9. 2011
    To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) and to assess their impact on disease progression.
  38. ncbi Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
    Guillermo Garcia-Manero
    University of Texas, MD Anderson Cancer Center, Box 428, 1515 Holcombe Blvd, Houston, TX 77025, USA
    J Clin Oncol 29:2521-7. 2011
    ..safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
  39. ncbi Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
    Lewis R Silverman
    Department of Medicine Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer 117:2697-702. 2011
    ....
  40. ncbi NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
    Daniella M B Kerbauy
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, PO Box 19024, Seattle, WA, 98109-1024, USA
    Blood 106:3917-25. 2005
    ..However, the data also suggest that combinations of ATO with agents that interfere with other pathways, such as FLIP autoamplification via NF-kappaB, may have considerable therapeutic activity...
  41. ncbi Clinical effect of point mutations in myelodysplastic syndromes
    Rafael Bejar
    Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 364:2496-506. 2011
    b>Myelodysplastic syndromes are clinically heterogeneous disorders characterized by clonal hematopoiesis, impaired differentiation, peripheral-blood cytopenias, and a risk of progression to acute myeloid leukemia...
  42. ncbi Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
    Thomas Prebet
    Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    J Clin Oncol 29:3322-7. 2011
    ..The outcome of these patients has not yet been described...
  43. ncbi Unraveling the molecular pathophysiology of myelodysplastic syndromes
    Rafael Bejar
    Brigham and Women s Hospital, Karp Research Building, CHRB 05 211, 1 Blackfan Cir, Boston, MA 02115, USA
    J Clin Oncol 29:504-15. 2011
    Somatically acquired genetic abnormalities lead to the salient features that define myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation, peripheral cytopenias, and risk of progression to acute myeloid leukemia...
  44. ncbi Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*
    Valeria Santini
    Azienda Ospedaliera Universitaria Careggi, Florence, Italy
    Eur J Haematol 85:130-8. 2010
    ..We present previously unpublished data from two large phase III trials describing common adverse events (AEs) associated with azacitidine and methods to manage them...
  45. ncbi Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes
    Asaka Kondo
    Division of Hematology, Department of Medicine, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo, Japan
    Blood 116:1124-31. 2010
    During disease progression in myelodysplastic syndromes (MDS), clonal blasts gain a more aggressive nature, whereas nonclonal immune cells become less efficient via an unknown mechanism...
  46. ncbi Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion
    Pierre Fenaux
    Hopital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France
    Leuk Res 34:1410-6. 2010
    ..in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals...
  47. ncbi Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation
    R Zeiser
    Department of Hematology and Oncology, Freiburg University Medical Center, Albert-Ludwigs University, Freiburg, Germany
    Leukemia 19:814-21. 2005
    ....
  48. ncbi Current and future management options for myelodysplastic syndromes
    Jeffrey Bryan
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 70:1381-94. 2010
    The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease...
  49. ncbi Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
    Hagop M Kantarjian
    Leukemia Department, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 116:3163-70. 2010
    ..efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or intermediate-risk myelodysplastic syndromes (MDS) receiving azacitidine therapy...
  50. ncbi Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
    Raphael Itzykson
    Clinique Hôpital Avicenne, Assistance Publique Hopitaux de Paris, Paris, France
    Blood 117:403-11. 2011
    ..In conclusion, routine tests can identify subgroups of patients with distinct prognosis with AZA treatment...
  51. ncbi Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes
    John F Seymour
    Peter MacCallum Cancer Centre and University of Melbourne, Victoria 3002, Australia
    Crit Rev Oncol Hematol 76:218-27. 2010
    ..Given this efficacy and tolerability, AZA should be considered the treatment of choice in patients aged ≥ 75 years with good performance status and higher-risk MDS...
  52. ncbi Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review
    Paolo Bernasconi
    Division of Haematology, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 142:695-708. 2008
    The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are both hematopoietic stem cell disorders...
  53. ncbi Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions
    Nathalie Douet-Guilbert
    Laboratoire d Histologie, Embryologie et Cytogenetique, Faculte de Medecine et des Sciences de la Sante, Universite de Bretagne Occidentale, Brest, France
    Ann Hematol 87:537-44. 2008
    Deletion of the long arm of chromosome 20 is a recurrent abnormality observed in myelodysplastic syndromes (MDS) and in Philadelphia-chromosome-negative myeloproliferative disorders (MPD)...
  54. ncbi Risk factors of myelodysplastic syndromes: a case-control study
    S S Strom
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 19:1912-8. 2005
    Little is known about the etiology of myelodysplastic syndromes (MDS)...
  55. ncbi Occupational exposures and haematological malignancies: overview on human recent data
    Alexis Descatha
    Unité de pathologie professionnelle et de santé au travail, Hôpital R Poincaré, AP HP 92380 Garches, France
    Cancer Causes Control 16:939-53. 2005
    ..Occupational causes of haematological malignancies are relatively uncommon, under-studied and under-identified. They are also often unrecognized by clinicians. This review summarizes the principal epidemiologic studies on this topic...
  56. ncbi Epidemiology of myelodysplastic syndromes
    Sara S Strom
    Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Semin Hematol 45:8-13. 2008
    b>Myelodysplastic syndromes (MDS) are one of the most common hematological conditions among the elderly. Differences in disease classification and diagnosis have made population-based studies an arduous endeavor...
  57. ncbi Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop
    Mette K Andersen
    Cytogenetic Laboratory, Section of Hematology Oncology, Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark
    Genes Chromosomes Cancer 33:395-400. 2002
    ..Response rates to intensive chemotherapy in this study were comparable to those of de novo disease...
  58. ncbi High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival
    Daniel T Starczynowski
    Department of Medical Biophysics, British Columbia Cancer Agency, Vancouver, Canada
    Blood 112:3412-24. 2008
    b>Myelodysplastic syndromes (MDSs) pose an important diagnostic and treatment challenge because of the genetic heterogeneity and poorly understood biology of the disease...
  59. ncbi Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation
    Marina Bousquet
    Institut National de Santé et de Recherche Médicale, U563, Centre de Physiopathologie de Toulouse Purpan, 31300 Toulouse, France
    J Exp Med 205:2499-506. 2008
    Most chromosomal translocations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) involve oncogenes that are either up-regulated or form part of new chimeric genes...
  60. ncbi Safety and efficacy of azacitidine in myelodysplastic syndromes
    Carlos E Vigil
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Drug Des Devel Ther 4:221-9. 2010
    ..The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed...
  61. ncbi A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndrome
    Alzbeta Vasikova
    Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Leuk Res 34:1566-72. 2010
    ..The results suggest that increased cell proliferation and resistance to apoptosis together with a loss of cell cycle control, damaged DNA repair and altered immune response may play an important role in malignant clone expansion in MDS...
  62. ncbi Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene
    A Minelli
    Biologia Generale e Genetica Medica, , C.P. 217, I 27100, Pavia, Italy
    Cancer Genet Cytogenet 124:147-51. 2001
    ..We postulate that, in fact, an inherited mutation in any of a group of mutator genes causes familial monosomy 7 also in the absence of a recognized mendelian disease, and that marrow chromosome 7 anomalies, in turn, lead to MDS/AML...
  63. ncbi NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia
    Ying-Wei Lin
    Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
    Blood 106:287-95. 2005
    The myelodysplastic syndromes (MDSs) are a group of clonal hematopoietic stem-cell disorders characterized by ineffective hematopoiesis and dysplasia...
  64. ncbi Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk
    Debra A Patt
    Department of Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:3871-6. 2007
    ..The purpose of this study was to determine the risk of developing acute myeloid leukemia (AML) after adjuvant chemotherapy for breast cancer in older women...
  65. ncbi Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
    Steven D Gore
    The Johns Hopkins Oncology Center, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 8:963-70. 2002
    ..Two patients on the 21/28 schedule developed hematological improvement. Prolonged infusions of PB are well tolerated making this an attractive platform for the clinical investigation of HDAC inhibition...
  66. ncbi Consensus statement on iron overload in myelodysplastic syndromes
    John M Bennett
    The Myelodysplastic Syndromes Foundation, Crosswicks, New Jersey, USA
    Am J Hematol 83:858-61. 2008
    In May 2005 at the 8th International Symposium on Myelodysplastic Syndromes (MDS), a consensus meeting was held on iron overload in MDS (Seymour, Hematol Oncol Clin 2005; Suppl 1:18-25)...
  67. ncbi Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide
    Claudio Praga
    Centre Oscar Lambret, Lille, France
    J Clin Oncol 23:4179-91. 2005
    ..Increased risk of secondary leukemia must be considered when assessing the potential benefit to risk ratio of higher than standard doses...
  68. ncbi A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers
    Anneclaire J De Roos
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Department of Epidemiology, University of Washington, Seattle, WA 98109 1024, USA
    Cancer Causes Control 18:1199-208. 2007
    b>Myelodysplastic syndromes (MDS) following treatment with chemotherapy or irradiation are termed 'secondary' MDS...
  69. ncbi Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications
    Irene Lorand-Metze
    Department of Internal Medicine, Hemocentro State University of Campinas, PO Box 6198, BR 13081 970, Campinas, SP, Brazil
    Leuk Res 28:587-94. 2004
    The WHO classification for myelodysplastic syndromes (MDS) has introduced new categories with prognostic relevance...
  70. ncbi Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group
    Andreas Josting
    First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    J Clin Oncol 21:3440-6. 2003
    ..To assess the incidence and outcome of secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients with Hodgkin's disease (HD)...
  71. ncbi Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
    Norbert Gattermann
    Heinrich Heine University, Dusseldorf, Germany
    Leuk Res 34:1143-50. 2010
    The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-naïve...
  72. ncbi Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members
    Aruna Padmanabhan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    Leuk Res 32:1820-3. 2008
    ..and radiation therapy for breast cancer are associated with therapy-related acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS), but little is known about additional risk factors...
  73. ncbi In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome
    Eugenia Flores-Figueroa
    Oncological Research Unit, Oncology Hospital, National Medical Center, IMSS, Av. Cuauhtemoc 330, Mexico DF 06720, Mexico
    Leuk Res 26:677-86. 2002
    ..indicating that there are alterations in the function of microenvironment (adherent) cell layers from myelodysplastic syndromes (MDS) marrow...
  74. ncbi Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect
    H Chen
    National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA
    Lancet 347:295-7. 1996
    ..to various cytotoxic and genotoxic agents, including those associated with increased risk of the myelodysplastic syndromes (MDS)...
  75. ncbi Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
    Zuzana Sieglova
    Institute of Hematology and Blood Transfusion, U Nemocnice 1, Prague, Czech Republic
    Leuk Res 28:1013-21. 2004
    Telomere length was evaluated by terminal repeat fragment method (TRF) in 50 patients with myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) arising from MDS and in 21 patients with untreated primary AML to ascertain, ..
  76. ncbi The role of apoptosis in the pathogenesis of the myelodysplastic syndromes
    J E Parker
    The Department of Haematological Medicine, Guy's, King's, Thomas' School of Medicine, London, UK
    Int J Hematol 73:416-28. 2001
    The paradoxical occurrence of peripheral cytopenias despite a normo/hypercellular marrow in myelodysplastic syndromes (MDS) has been attributed to excessive intramedullary hematopoietic cell apoptosis...
  77. ncbi Impact of iron overload in myelodysplastic syndromes
    Pierre Fenaux
    Groupe Francophone des Myélodysplasies, France
    Blood Rev 23:S15-9. 2009
    Anaemia is prevalent in patients with myelodysplastic syndromes (MDS), and most patients with MDS receive regular red blood cell transfusions, which can lead to iron overload...
  78. ncbi Cause of death in patients with lower-risk myelodysplastic syndrome
    Farshid Dayyani
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:2174-9. 2010
    ..The cause of death (COD) of these patients is not well understood. Identifying the COD could help to guide early therapy decisions...
  79. ncbi Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome
    M Iwai
    Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Leukemia 19:1367-75. 2005
    ..These results suggested that FHIT methylation was accumulated through the disease progression of MDS and AML, and the role of the FHIT gene as a tumor suppressor seemed different in AML and MDS...
  80. ncbi Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study
    Cheri E Klein
    Department of Biopharmaceutical Sciences, The University of Illinois at Chicago, 833 South Wood Street (MC 865, Chicago, IL 60612, USA
    Cancer Chemother Pharmacol 57:199-206. 2006
    ..medication adherence, pharmacokinetics and exposure versus response relationships in patients with myelodysplastic syndromes (MDS). METHODS: Ninety adult patients with MDS received oral topotecan (1...
  81. ncbi Significance of JAK2 and TET2 mutations in myelodysplastic syndromes
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Blood Rev 24:83-90. 2010
    The pathogenesis of myelodysplastic syndromes involves a pattern of genetic, epigenetic, and immune-mediated mechanisms but little is known about what causes the specific disease features and promotes disease progression in the ..
  82. ncbi Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders
    Irene Lorand-Metze
    Department of Internal Medicine, Hemocentro, State University of Campinas, P O Box 6198, BR 13081 970 Campinas, Sao Paulo, Brazil
    Leuk Res 31:147-55. 2007
    The diagnosis of myelodysplastic syndromes (MDS) is based on peripheral cytopenias, bone marrow (BM) morphology and karyotyping. This may be difficult in cases with few dysplastic elements in BM and a normal karyotype...
  83. ncbi Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia
    H Kurotaki
    Department of Pathology, Hirosaki University School of Medicine, Hirosaki, Japan
    Acta Haematol 102:115-23. 2000
    ....
  84. ncbi Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population
    M Maynadie
    Registre des Hémopathies Malignes de Côte d Or, Equipe associée INSERM DGS, Dijon, France
    Br J Cancer 74:288-90. 1996
    Data on myelodysplastic syndromes (MDS) are seldom collected by cancer registries and unbiased findings from population-based studies remain rare...
  85. ncbi Myelodysplastic syndromes: From pathogenesis and prognosis to treatment
    Pierre Fenaux
    Service d Hematoilogie, Clinicique Paris XIII University, Avicenne Hospital, France
    Semin Hematol 41:6-12. 2004
    b>Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenia and by increased progression to acute myelocytic leukemia (AML)...
  86. ncbi Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes
    L Ma
    Laboratory for Experimental Hematology, University of Leuven, Leuven, Belgium
    Leukemia 18:1451-6. 2004
    ..lymphoid precursor dendritic cell (pDC) counts were determined in peripheral blood from 22 patients with myelodysplastic syndromes (MDS) by a single-platform flow cytometric protocol...
  87. ncbi Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia
    M F Johan
    Br J Haematol 124:843-4. 2004
  88. ncbi Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease
    Manuel Aivado
    Proteomics Core and Department of Medical Oncology, Dana Farber Harvard Cancer Center, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 104:1307-12. 2007
    b>Myelodysplastic syndromes (MDS) are among the most frequent hematologic malignancies. Patients have a short survival and often progress to acute myeloid leukemia...
  89. ncbi Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States
    Thomas F Goss
    Covance Market Access Services Inc, Gaithersburg, MD 20878, USA
    Cancer Control 13:17-25. 2006
    Lenalidomide has been approved for the treatment of transfusion-dependent low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a chromosome 5q deletion with or without additional cytogenetic abnormalities...
  90. ncbi The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines
    Peter L Greenberg
    Stanford University Cancer Center, Stanford, California 94305 5821, USA
    J Natl Compr Canc Netw 6:942-53. 2008
    Guidelines for management of patients with myelodysplastic syndromes (MDS) have been generated by the National Comprehensive Cancer Network (NCCN) Myelodysplastic Syndromes Panel...
  91. ncbi Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome
    A M Jankowska
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Leukemia 22:551-8. 2008
    In myelodysplastic syndromes (MDS) increased chromosomal breaks point toward defects in DNA repair machinery including base excision repair (BER) pathway involved in handling of oxidative DNA damage...
  92. ncbi Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes
    Virginia M Klimek
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:826-32. 2008
    ..study was to evaluate the toxicity, pharmacokinetic profile, and selected pharmacodynamic properties of the histone deacetylase inhibitor depsipeptide in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML).
  93. ncbi Treatment strategies in myelodysplastic syndromes
    Ehab Atallah
    Department of Neoplastic Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Cancer Invest 26:208-16. 2008
    b>Myelodysplastic syndromes (MDS) are a group of disorders characterized by progressive cytopenias and transformation to acute leukemia. Over the last four years, we have experienced a revolution in the treatment of MDS...
  94. ncbi Current status of epigenetic treatment in myelodysplastic syndromes
    Andrea Kuendgen
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Ann Hematol 87:601-11. 2008
    ..The first treatment approved by the Food and Drug Administration for the treatment of myelodysplastic syndromes (MDS) was the DNMT-inhibitor 5-azacytidine...
  95. ncbi Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?
    A Cortelezzi
    Servizio Autonomo di Ematologia Diagnostica, Ospedale Maggiore, IRCCS, Milano, Italy
    Hematol J 1:153-8. 2000
    Iron overload is usually observed in patients (even untransfused) with myelodysplastic syndromes (MDS), and contributes towards the generation of low molecular weight iron complexes or non-transferrin-bound iron (NTBI), which in turn ..
  96. ncbi 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop
    Clara D Bloomfield
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Genes Chromosomes Cancer 33:362-78. 2002
    ..We conclude that among t-MDS/t-AL patients with balanced aberrations, 11q23 translocations are an independent adverse risk factor. Although BMT is the current therapy of choice, new treatment is required...
  97. ncbi Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes
    W K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Boulevard, Suite B213, Los Angeles, CA 90048, USA
    Leuk Res 25:855-8. 2001
    To understand the underlying mechanisms in myelodysplastic syndromes (MDS) by identifying target tumor suppressor genes, we performed a detailed deletional mapping of the short arm of chromosome 1 in 38 paired samples of bone marrow and ..
  98. ncbi Changing the treatment paradigm in myelodysplastic syndromes
    Ghulam J Mufti
    Kings College London and Kings College Hospital, Department of Haematological Medicine, London SE5 9RS UK
    Cancer Control 15:14-28. 2008
    ..Timing of available therapies, including stem cell transplantation, should be incorporated into the new treatment paradigm, with end goals of prolonging survival and optimizing patient outcomes...
  99. ncbi Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10)
    Hui-Hua Hsiao
    The First Department of Internal Medicine; Department of Internal Medicine, Kaohsiung Medical University Hospital, 100, Tz-You 1st Road, Kaohsiung 807, Taiwan
    Cancer Genet Cytogenet 165:161-6. 2006
    We analyzed 23 patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) showing a der(1;7)(q10;p10) [hereafter der(1;7)] to identify the exact predictive factor of this cytogenetic change. Eight (34...
  100. ncbi A prognostic score for patients with lower risk myelodysplastic syndrome
    G Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 22:538-43. 2008
    Current prognostic models for myelodysplastic syndromes (MDS) do not allow the identification of patients with lower risk disease and poor prognosis that may benefit from early therapeutic intervention...
  101. ncbi High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration
    K Paulsson
    Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
    Leukemia 20:840-6. 2006
    ..sole chromosome aberration is the most common numerical abnormality in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), little is known about its pathogenetic effects...

Research Grants75

  1. NF1 GENE IN MYELOID LEUKEMIA AND CYTOKINE SIGNALING
    DAVID LARGAESPADA; Fiscal Year: 2002
    DESCRIPTION: (adapted from the investigator's abstract) Treatment of childhood myelodysplastic syndromes (MDS) as well as chronic and acute myeloid leukemia (CML and AML) remains disappointing compared with well known advances in the ..
  2. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Myelodysplastic syndromes (MDS) is a heterogeneous group of bone marrow failure states characterized by dysplastic hematopoiesis, ..
  3. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2011
    ..PUBLIC HEALTH RELEVANCE: Myelodysplastic syndromes (MDS) is a heterogeneous group of bone marrow failure states characterized by dysplastic hematopoiesis, ..
  4. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Pearlie K Epling Burnette; Fiscal Year: 2009
    b>Myelodysplastic syndromes (MDS) are characterized by incompetent hematopoiesis that leads to single or multi-lineage peripheral cytopenias with the development of acute myeloid leukemia (AML) in approximately 30-40% of cases...
  5. A mouse model of myelodysplastic syndrome progression and leukemic stem cells
    Yupo Ma; Fiscal Year: 2009
    ..Expiration Date: 04/30/2008 Principal Investigator/Program Director (Last, first, middle): Ma, Yupo Myelodysplastic syndromes (MDS) are stem-cell malignancies most frequently seen among elderly patients, resulting in a high annual ..
  6. MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS
    Edward Newman; Fiscal Year: 2001
    ..in the treatment of acute myeloid leukemia and likely therapeutic utility in other leukemias and myelodysplastic syndromes. After incorporation into DNA, DAC inhibits the enzyme DNA (cytosine-5)-methyltransferase (MT'ase)...
  7. New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)
    Elihu Estey; Fiscal Year: 2007
    The incidence of myelodysplastic syndromes (MDS) is likely to increase as the U.S. population ages. Nonetheless, there are no satisfactory treatments...
  8. Cyclin E Regulation in Normal and Neoplastic Hematopoiesis
    ALEXANDER C MINELLA; Fiscal Year: 2010
    ..These features are characteristics of hematopoietic cells of patients with early-stage myelodysplastic syndromes (MDS)...
  9. FMS TRANSFORMATION/CSF-1 RECEPTOR SIGNAL TRANSDUCTION
    Martine Roussel; Fiscal Year: 1993
    ..human FMS might contribute to the etiology of myeloid proliferative disorders, including leukemias and myelodysplastic syndromes, but no bona fide activating mutations at codon 301 have thus far been identified...
  10. The Role of the APC Tumor Suppressor Gene in Hematopoiesis and Leukemogenesis
    Zhijian Qian; Fiscal Year: 2010
    ..The myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells (HSCs), characterized by ineffective ..
  11. Targeted Therapy of Lyn in Myelodysplastic Syndrome
    SETH JOEL COREY; Fiscal Year: 2010
    b>Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell transplant...
  12. Targeted Therapy of Lyn in Myelodysplastic Syndrome
    Seth Corey; Fiscal Year: 2006
    b>Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell transplant...
  13. Targeted Therapy of Lyn in Myelodysplastic Syndrome
    Seth Corey; Fiscal Year: 2007
    b>Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell transplant...
  14. Clinical Hematology Research Career Development Program (K12)
    Ellis Neufeld; Fiscal Year: 2007
    ..and thalassemia; hemophilia and other hemostatic disorders; venous thromboembolism and thrombophilias; myelodysplastic syndromes and myeloproliferative disorders; transfusion medicine, including unique aspects of pediatric ..
  15. Contribution of the vascular niche to the hematopoietic reconstitution.
    Shahin Rafii; Fiscal Year: 2010
    ..and HSC self-renewal will offer new strategies to treat BM failure states, including aplastic anemia, myelodysplastic syndromes and accelerate BM reconstitution after chemotherapy, irradiation and transplantation...
  16. Modeling Multi-step Leukemogenesis in Nf1 and Kras Mutant Mice
    JENNIFER LAUCHLE; Fiscal Year: 2007
    ..In contrast, myelodysplastic syndromes (MDSs) are usually associated with low blood cell counts and aberrant bone marrow morphology, while ..
  17. Bone Marrow Failure Clinical Research Center
    Jaroslaw Maciejewski; Fiscal Year: 2006
    ..cytopenias including large granular lymphocyte leukemia and pure red cell aplasia, and various myelodysplastic syndromes. This application presents a multi-targeted approach to improving the medical therapy for IBMFS&C ..